Revolution Medicines Inc. (RVMD)
39.85
-2.72 (-6.39%)
At close: Jan 14, 2025, 3:59 PM
41.82
4.94%
After-hours Jan 14, 2025, 07:28 PM EST
undefined% (undefined)
| Bid | 15.94 |
| Market Cap | 7.27B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.66 |
| PE Ratio (ttm) | -10.89 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 45.67 |
| Volume | 1,786,473 |
| Avg. Volume (20D) | 1,595,004 |
| Open | 42.86 |
| Previous Close | 42.57 |
| Day's Range | 39.52 - 42.97 |
| 52-Week Range | 25.93 - 62.40 |
| Beta | undefined |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2020
Employees 490
Stock Exchange NASDAQ
Ticker Symbol RVMD
Website https://www.revmed.com
Analyst Forecast
According to 11 analyst ratings, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is $67, which is an increase of 68.13% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Revolution Medicines Inc. is scheduled to release its earnings on Feb 24, 2025,
during market hours.
Analysts project revenue of $750.00K, reflecting a 1.08% YoY growth and earnings per share of -0.98, making a -14.04% decrease YoY.
Analysts project revenue of $750.00K, reflecting a 1.08% YoY growth and earnings per share of -0.98, making a -14.04% decrease YoY.
1 month ago ·
Source
-10.46%
Revolution Medicines shares are trading lower. The...
Unlock content with
Pro Subscription
6 months ago ·
Source
+10.97%
Revolution shares are trading higher after the company announced that it will host an investor webcast to provide an update on its RMC-6236 pancreatic ductal adenocarcinoma clinical development program.
